Physician profile
Aaron J Ward
NPI 1245380120
$15,314.55
in general payments reported to CMS, 2019-2025
41 companies · $15.61 in 2025
The $15.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $231 · 2021: $373 · 2022: $5,243 · 2023: $8,071 · 2024: $263 · 2025: $15.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,915 · Food and Beverage: $1,273 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,915.00 |
| Food and Beverage | $1,273.00 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $4,101.72 | 2019-2022 | |
| Senseonics, Incorporated | $4,000.00 | 2023 | Eversense |
| Ascensia Diabetes Care US INC. | $3,262.14 | 2021-2024 | |
| Novo Nordisk INC | $679.29 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $583.33 | 2019-2024 | Mounjaro, Jardiance, Baqsimi |
| Astrazeneca Pharmaceuticals LP | $539.10 | 2019-2023 | Farxiga |
| Amgen INC. | $301.95 | 2019-2024 | Prolia, Evenity, Tepezza |
| Corcept Therapeutics | $158.56 | 2022-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $147.06 | 2019-2024 | |
| Abbott Laboratories | $141.73 | 2022-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $125.40 | 2021-2024 | Minimed 780g |
| Zealand Pharma US, INC. | $116.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.51 | 2019-2023 | Jardiance |
| Tandem Diabetes Care, INC. | $105.53 | 2019-2022 | |
| Mannkind Corporation | $101.85 | 2019-2023 | Afrezza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $71.07 | 2019-2022 | |
| Insulet Corporation | $67.71 | 2019 | |
| Recordati_rare_diseases_inc. | $57.04 | 2023-2024 | Isturisa, Signifor Lar |
| Amryt Pharma Holdings LTD | $56.40 | 2022-2023 | Mycapssa |
| Horizon Therapeutics Plc | $54.11 | 2020-2023 | Tepezza |
| Valeritas, INC. | $44.55 | 2019 | |
| Xeris Pharmaceuticals, INC. | $41.40 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $39.62 | 2023-2024 | Strensiq |
| Amarin Pharma, INC. | $38.50 | 2019 | |
| Halozyme INC | $34.27 | 2023 | |
| Beta Bionics, INC. | $31.47 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lifescan, INC. | $29.86 | 2019-2020 | |
| Abbvie INC. | $29.54 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $28.16 | 2019-2022 | |
| Esperion Therapeutics, INC. | $27.48 | 2020-2022 | |
| Radius Health, INC. | $25.68 | 2019-2023 | Tymlos |
| Ibsa Pharma INC. | $25.65 | 2019-2022 | |
| Nevro Corp. | $21.86 | 2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $19.74 | 2023 | |
| Eisai INC. | $19.65 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.69 | 2023 | Inpefa |
| Chiesi USA, INC. | $15.95 | 2024 | Mycapssa |
| Amneal Pharmaceuticals LLC | $15.34 | 2024 | Unithroid |
| Cequr Corporation | $14.65 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.